NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied ...

Fintel reports that on December 2, 2024, UBS downgraded their outlook for Applied Therapeutics (NasdaqGM:APLT) from Buy to ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Fintel reports that on November 29, 2024, RBC Capital downgraded their outlook for Applied Therapeutics (NasdaqGM:APLT) from ...

NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied ...

Applied Therapeutics stock (APLT) was down 75% early Friday on news the FDA had declined to approve its drug govorestat, ...

Applied Therapeutics stock plummets 77% after the FDA issues a CRL for the company's NDA seeking approval for govorestat to treat classic galactosemia.

Applied Therapeutics (NASDAQ:APLT – Free Report) had its price objective lowered by Citigroup from $13.00 to $8.00 in a ...

Applied Therapeutics said on Monday it received a warning letter limited to a trial studying its genetic disease drug, after ...

Applied Therapeutics (NASDAQ:APLT – Free Report) had its price objective reduced by Robert W. Baird from $14.00 to $5.00 in a ...

Applied Therapeutics APLT announced that the FDA has issued a Complete Response Letter (CRL) for the new drug application (NDA) seeking approval for APLT’s lead candidate, govorestat ...

The stock of Applied Therapeutics (APLT) plunged 75% in a single trading session on November 29 after the U.S. Food and Drug Administration (FDA) ruled against the biotechnology company’s drug ...